MDSpire - Takeaway
Clinical Guidelines
Feature

Japan Clears First iPSC Therapies for Clinical Use 

Two iPSC-derived cell therapies receive time-limited authorization following early clinical trials

  • March 25, 2026

  • 2 min

Share

  • 1

    Japan's MHLW granted conditional approval to two stem cell therapies.

  • 2

    ReHeart is for severe ischemic heart failure.

  • 3

    Amchepry targets Parkinson's disease.

  • 4

    Both were derived from induced pluripotent stem cells.

  • 5

    Early trials showed safety but require larger studies.

  • 6

    Approval allows continued monitoring of patient outcomes.

  • 7

    Japan’s initiative pushes for faster regenerative medicine development.

Original Source(s)

Japan Clears First iPSC Therapies for Clinical Use 

  • March 25, 2026

Related Content

Gonococcal Endocarditis Diagnosed by PCR

Case highlights diagnostic challenges when blood cultures are negative and embolic complications are present

A Closer Look at Vascular Cell States in Marfan Syndrome

Single-cell proteomics identifies Marfan-enriched smooth muscle states and endothelial transition signatures

  • March 25, 2026

  • 2 min
Suspended Lead Suits Linked to Lower Radiation in LAAO

Study shows suspended lead suits reduce head-level radiation exposure during left atrial appendage occlusion procedures